Background and aims The activity of CYP2A6, the major nicotine-inactivating enzyme, is measurable in smokers using
INTRODUCTION
The prevalence of cigarette smoking remains high, despite widespread tobacco control efforts; recent estimates suggest that 15% of Americans are current smokers [1] . A growing segment of American smokers are light smokers (smoke ≤ 10 cigarettes/day) who, like heavy smokers, experience elevated risks of disease and mortality compared to never smokers [2] . Smoking behaviour and smokingrelated morbidity differ by ethnicity. For instance, although African American (AA) smokers on average smoke fewer cigarettes/day than European American (EA) smokers, the level of total nicotine equivalents, a biomarker of total nicotine intake, is similar in AA and EA smokers, suggesting more intensive smoking (e.g. greater puff volume) among AAs [3] . At an equivalent number of cigarettes per day, the risk for lung cancer is higher in AA compared to EA smokers, due in part perhaps to more intensive smoking and, therefore, greater exposure to tobaccospecific nitrosamines and other harmful chemicals [4] . Of note, AA (versus EA) smokers are also more likely to make quit attempts and are less likely to achieve cessation [5] . Understanding the factors that contribute to this increased risk for lung cancer and reduced likelihood of cessation among AA smokers will help to guide treatment interventions for this population.
Nicotine is the predominant psychoactive compound in cigarettes [6] . Nicotine undergoes metabolic inactivation by the hepatic CYP2A6 enzyme to cotinine, which is metabolized further to 3 0 hydroxycotinine exclusively by CYP2A6 [7, 8] . The CYP2A6 gene, located on chromosome 19q13.2, contains several functional polymorphisms, leading to interindividual variation in the rate of nicotine clearance [9] . The nicotine metabolite ratio (NMR; 3 0 hydroxycotinine/cotinine) is an established and validated phenotypical marker of CYP2A6 activity in smokers; it is associated with the CYP2A6 genotype and correlates with nicotine clearance [10] [11] [12] [13] [14] [15] . The NMR is 80% heritable (estimated in Finnish European twins) [16] ; in addition to genetic influences, the NMR captures relatively minor environmental [e.g. mentholated cigarette use and body mass index (BMI)] [17, 18] sources of variation in CYP2A6 activity. The NMR has been evaluated as a clinical marker for personalizing smoking cessation treatment. Compared to higher NMR, lower NMR (i.e. slower nicotine metabolism) is associated with higher cessation rates with behavioural counselling [19] and among nicotine patch-treated smokers [20] [21] [22] . In a placebo-controlled bupropion trial, bupropion increased quit rates over placebo in those with higher but not lower NMR [19] . In smokers randomized prospectively to treatment based on the NMR [Pharmacogenetics of Nicotine Addiction Treatment (PNAT)2 trial; NCT01314001), those with higher, but not lower, NMR had higher quit rates on varenicline (versus nicotine patch) [23] . Number-needed-to-treat analyses in smokers with higher NMR indicated that five and 26 smokers would need to be treated with varenicline (versus placebo) and nicotine patch (versus placebo), respectively, for one smoker to quit, again indicating the superiority of varenicline for those with higher NMR [23] ; in those with lower NMR these values were 8 and 10, respectively. In addition, those with lower (versus higher) NMR experienced greater negative side effects on varenicline (versus placebo) [23] . Thus, the evidence indicates that smokers with higher NMR show greater benefit from varenicline or bupropion compared to behavioural counselling or nicotine patch, while smokers with lower NMR are treated more effectively and safely with nicotine patch and/or behavioural counselling.
Variability in CYP2A6 genetics and/or the NMR also influences the level of tobacco consumption (from cigarettes and smokeless tobacco), dependence and risk for tobaccorelated disease; smokers with slower metabolism (i.e. slow CYP2A6 metabolism groups or lower NMR values) generally show lower consumption, dependence and disease risk [17, [24] [25] [26] .
The NMR varies by ethnicity, with AA smokers having on average lower NMR (and nicotine clearance) versus smokers of EA descent [17, 27] , due in part to the higher frequency of known CYP2A6 reduced or loss-of-function variants in AAs [28] ; many of these variants, including *23, *24, *25, *28, *35, and *39-*45 [29] [30] [31] [32] , were identified and characterized functionally by our group using invitro (e.g. CYP2A6 cDNA expression system), ex-vivo (e.g. human liver bank) and in-vivo (e.g. human smokers) nicotine metabolism rate assessments. These variants are common (> 1% frequency) in AA, but exceedingly rare in EA populations. CYP2A6*17, with an allele frequency of 10% in AA [33] , explains~8% of the variability in the NMR (unpublished observations in the Kick-it-at-Swope (KIS3) trial [34] ). Although > 40 CYP2A6 variants have been identified and characterized functionally, estimates in Finnish Europeans indicate that only~30% of NMR variation is explained currently by detected CYP2A6 variants [16] . To date, three NMR genome-wide association studies (GWASs) have been performed, predominantly or exclusively in whites who were non-treatment-seeking smokers (only 413 AA total among > 4000 total participants from three studies) [16, 35, 36] ; no GWAS has examined the NMR in smokers seeking treatment, for whom personalized medicine approaches based on CYP2A6/the NMR would be targeted.
In this study we performed a GWAS of the NMR, assessed at baseline when participants were smoking ad libitum (i.e. when NMR is stable [13] ), in AA smokers from two smoking cessation clinical trials and genotyped top hits in a third trial to confirm associations with the NMR. The first involved heavy smokers (≥ 10 cigarettes/day) screened for the PNAT2 trial (NCT01314001), where smokers were randomized to placebo, nicotine patch or varenicline [23] . The second involved light smokers (≤ 10 cigarettes/day) who participated in a placebo-controlled bupropion trial for smoking cessation (KIS3 trial; NCT00666978) [34, 37] . To investigate further the associations between selected GWAS hits and the NMR, we utilized a third sample of AA light smokers from a placebo-controlled nicotine gum trial (KIS2 trial) [38] . Our goals were to understand more clearly the genetic underpinnings of the NMR in AA smokers, and to compare genetic signals with those found previously in European populations to identify potential common and unique genetic influences on the NMR in AA smokers.
METHODS
The original trial protocols were approved by institutional review boards at all participating sites and at the University of Toronto. Individuals providing written informed consent for DNA sample collection and release of de-identified information to investigators underwent genotyping.
PNAT2 clinical trial (NCT01314001) [23]
Participant characteristics and trial procedures are described in detail elsewhere [17, 23] . Briefly, eligible adult (aged 18-65 years) smokers (≥ 10 cigarettes/day) from four clinical sites (University of Pennsylvania, University of Toronto/Centre for Addiction and Mental Health, MD Anderson and the State University of New York at Buffalo) were randomized prospectively based on their pretreatment NMR to receive placebo, nicotine patch or varenicline treatment for smoking cessation.
KIS3 clinical trial (NCT00666978) [34]
Participant characteristics and clinical trial procedures are described in detail elsewhere [34, 37] . Briefly, eligible adult (aged ≥ 18 years) light smokers (≤ 10 cigarettes/day) from Kansas City, MO were randomized to bupropion plus health education or placebo plus health education for smoking cessation.
KIS2 clinical trial [38]
Participant characteristics and clinical trial procedures are described in detail elsewhere [38] . Briefly, eligible adult (aged ≥ 18 years) light smokers (≤ 10 cigarettes/day) from Kansas City, MO, were randomized to nicotine gum or placebo and health education or motivational interviewing for smoking cessation. Fig. S1 ). QC procedures were performed using PLINK (version 1.07) [39] and R software. The PNAT2 AA and KIS3 AA genotypes were then phased using SHAPEIT [40] and imputed using IMPUTE2 [41] . The genomic data were divided into individual chromosomes (chromosomes and aligned against the reference panel (phase I release of 1000 genomes). Following the elimination of duplicated SNPs a second alignment step was performed, followed by pre-phasing and imputation, according to previously established protocols [41] [42] [43] [44] . Variants with INFO (i.e. imputation quality) scores > 0.4 (a threshold of 0.3 or higher is recommended [45] ) and a minor allele frequency > 1% were selected for further analyses. Overall, 17 970 591 and 17 919 969 variants in PNAT2 and KIS3, respectively, were available for analysis.
Assessment of imputation quality for CYP2A6 relative to other chromosome 19 genes CYP2A6 shares high homology with CYP2A7 and CYP2A13, which can confound the accuracy of CYP2A6 calls [46] . IMPUTE2 INFO (i.e. imputation quality) scores for CYP2A6 were compared to those of EIF3K and TGFβ1, located outside this region of high homology (~2222 kb 5 0 and~480 kb 3 0 of CYP2A6, respectively).
Phenotype: NMR
The levels of cotinine and 3 0 hydroxycotinine were determined from blood samples collected at intake when participants were smoking ad libitum using identical liquid chromatography-tandem mass spectrometry, according to previously established protocols [10, 11, 47] . The NMR (3 0 hydroxycotinine/cotinine) was square-roottransformed to correct for positive skew (Supporting information, Fig. S3 ). Individuals with cotinine values below 10 ng/ml, suggestive of non-daily smoking [48] , were excluded from analyses.
Covariates
Analyses in PNAT2 and KIS3 included principal components 1 and 2 as covariates to control for possible effects of population stratification [49] . To identify additional covariates, we performed separate linear regression analyses to identify whether factors previously associated significantly with the NMR in the whole PNAT2 sample (sex, age, oestrogen-containing therapy use, BMI, alcohol use [17] ) were associated with square-root NMR (with P < 0.10) in PNAT2 AA and KIS3 AA. In PNAT2, the following were included as covariates: sex (P = 0.038), age (P = 0.006), BMI (P = 0.038) and use of menthol cigarettes (P = 0.063). In KIS3, the following were included as covariates: sex (P = 0.056), age (P < 0.001) and BMI (P < 0.001), but not mentholated cigarette use (P = 0.60).
STATISTICAL ANALYSES

GWAS of the NMR
SNPTEST (version 2.5.2) was used to identify genetic associations with the NMR separately in PNAT2 and KIS3; chromosomes 1-22 were analysed separately. Frequentist additive models were specified, and genotype uncertainty was controlled for using the '-method expected' option (uses expected genotype counts or genotype dosages). We also performed a separate set of analyses specifying frequentist dominant models, and the '-method score' option, and acquired similar results. Variants with P < 5e-8 were considered to be significant at the genome-wide level [50] .
A meta-analysis of chromosome 19 results, adjusting for population substructure and NMR covariates, was then performed using META (version 1.7) [51] . The genomic control inflation factor (λ) (calculated using PLINK) for the full GWAS analysis (chromosomes 1-22) was 1, and the QQ plots showed no deviation from the null (Supporting information, Fig. S4 ). Because the same phenotype (square-root NMR; Supporting information, Fig. S3 ) measured on the same scale was specified in both cohorts, the inverse-variance method based on a fixed-effects model was implemented [16] . Variants with INFO imputation quality scores ≥ 0.50 were included in the meta-analysis; a total of 367 834 markers were in the union list.
Conditional analysis of chromosome 19 NMR results in PNAT2 and KIS3
To identify putatively independent chromosome 19 signals associated with the NMR, conditional analyses were performed [16] ; the variant with the smallest P-value in the meta-analysis (i.e. rs12459249) was considered the first independent signal, and then 'conditioned on' (i.e. entered as a covariate) in subsequent frequentist additive models performed separately in PNAT2 and KIS3. These results were meta-analysed, with the variant with the smallest P-value (i.e. the second independent signal) entered as a covariate along with the first independent signal in the second round of conditional analyses. The procedure was repeated until no additional significant (i.e. P < 5e-8) signals emerged.
Proportion of variation in the NMR accounted for by rs12459249, rs111645190, rs2644890 and rs11879604
Separate linear regression models were used to determine the proportion of NMR variability attributable to selected variants (three-genotype coding), using SPSS version 23 (IBM, Armonk, NY, USA). The outcome measure was square-root NMR. Models in PNAT2 controlled for sex, age, BMI and the use of mentholated cigarettes, while models in KIS3 and KIS2 controlled for sex, age and BMI. The proportion of NMR variability accounted for by each variant was calculated by squaring the variant's part correlation coefficient and multiplying by 100.
FINAL SAMPLE SIZES
Two of the n = 506 PNAT2 AA participants were excluded from further analyses due to missing and outlying [> 4 standard deviations (SD) from the mean] square-root NMR values (Supporting information, Fig. S1 ). After additionally excluding individuals with missing menthol covariate data (n = 98), n = 406 PNAT2 participants were available for GWAS analysis. Eight KIS3 AA participants were excluded due to having cotinine levels < 10 ng/ml (Supporting information, Fig. S1 ), which suggests nondaily smoking, and one participant was missing BMI data. Thus, n = 449 KIS3 participants were available for GWAS analysis. Of the n = 495 KIS2 individuals with pretreatment NMR who provided a blood sample and consented to genetic testing, n = 15 were excluded from further analyses due to insufficient quantity of blood remaining (n = 7), cotinine level < 10 ng/ml (n = 6) and outlying (> 4 SD from the mean) square-root NMR values (n = 2). Thus, the final KIS2 AA sample comprised n = 480 individuals.
RESULTS
Characteristics of the final analysed sample are provided in Table 1 . These values are similar to those reported in the full trial samples [17, 34, 38] . In PNAT2 and KIS3, the median INFO imputation quality score (highest possible score of 1, with higher scores indicating higher imputation quality) for CYP2A6 was 0.9, compared to 0.6 and 0.9 for EIF3K and TGFβ1, respectively, suggesting adequate imputation quality for CYP2A6. In each of PNAT2 and KIS3, 98% of the variants associated significantly with the NMR at the genome-wide level (P < 5e-8) were located on chromosome 19, within or near to (several kilobases) the CYP2A6 gene. Of note, no genetic variants in UGT enzymes (involved in the glucuronidation of nicotine, cotinine and 3 0 hydroxycotinine [52] ) or the organic cation transporter 2 (OCT2) (involved in nicotine transport [52] ) reached genome-wide significance in either PNAT2 or KIS3.
Meta-analysis of chromosome 19 NMR results in PNAT2 and KIS3 AA smokers
Ninety-six genome-wide significant chromosome 19 variants were identified after adjusting for cohort-specific principal components 1 and 2 and NMR covariates (top 10 variants in Table 2 , full list in Supporting information, Table S2 ; all top variants had INFO (imputation quality) scores > 0.9). Of note, the top 10 variants did not differ (similar betas and P-values) when four principal components were adjusted for. The top (smallest P-value) overall variant in the meta-analysis was rs12459249 (I 2 = 0; heterogeneity P = 0.80), with a combined P-value of 1.47e-39 (Table 2) ; this was the top variant in PNAT2 (Fig. 1a) , and the second most significant variant in KIS3 (Fig. 1b) . Overall, 58 (60.4%) of the 96 significant hits were not genome-wide significant in the GWAS of the NMR performed in~1500 Finnish European smokers [16] ; the most significant of these 58 AA hits in the meta-analysis was rs111825958 (I 2 = 0.66; heterogeneity P = 0.32), with a combined P-value of 5.93e-26 (Table 2) . Effect sizes and P-values for the top variants in each population (PNAT2 and KIS3) are also provided in Table 2 . In a separate metaanalysis that controlled additionally for cigarettes/day and menthol use in KIS3, the top hit was rs11878604 with a beta of À0.68 [standard error (SE) = 0.069; P = 5.65e-23 per C versus T allele], while rs12459249 was the second top hit with a beta of 0.59 (SE = 0.063; P = 5.73e-21 per C versus T allele); In Kick-It-At-Swope (KIS3), GWAS results were adjusted for principal components 1 and 2, sex, age and BMI. The genomic inflation factor score (λ) in each population was 1 and therefore not adjusted for in the meta-analysis. These variants were not genome-wide significant in a study of~1500 Finnish European smokers [16] . NMR = nicotine metabolite ratio.
these effect sizes did not differ substantially from those in the primary analysis (Table 2 ).
Conditional analysis of chromosome 19 NMR results in African American smokers
Conditional analyses of the chromosome 19 NMR results in PNAT2 and KIS3 AA smokers revealed a total of three independent signals associated with the NMR; the first two were tagged by rs12459249 and rs111645190 (Table 3) . In PNAT2 and KIS3, rs12459249, located 9.5 kb 3 0 of CYP2A6, altered NMR substantially (Fig. 2a,b) , explaining 17.1 and 15.3% of the variability in the NMR, respectively. The association between the rs12459249 variant and the NMR also replicated in KIS2 (P = 1.30e-17; Fig. 2c ). After conditioning on rs12459249, rs111645190 (located~5.5 kb 5 0 of CYP2A6) had a P-value of 1.19e-11 (beta = À0.42 per A versus G allele; SE = 0.062; Table 3 and Fig. 1c,d ). In PNAT2 and KIS3, the influence of rs111645190 on the NMR was also pronounced (Fig. 2d,e) , explaining an additional 2.9 and 5.2% of the variation in the NMR, respectively, after controlling for rs12459249. Of note, in a separate meta-analysis that controlled additionally for cigarettes/day and menthol use in KIS3, the effect size for rs111645190 was similar to the primary analysis (Table 2 ) (beta = À0.67, SE = 0.085; P = 4.10e-15 per A versus G allele). The association for rs111645190 was also replicated in KIS2 (P = 1.77e-7; Fig. 2f ). After conditioning on both rs12459249 and rs111645190, a third independent signal emerged, tagged by rs185430475 (MAF = 2%; located >10 MB 3 0 of CYP2A6), with a P-value of 1.94e-8
(beta = 1.27 per G versus C allele; SE = 0.23). Of note, the rs185430475 variant was not associated significantly with the NMR in the meta-analysis (beta = 1.25 per G versus C allele; SE = 0.26; P = 9.26e-7), in PNAT2 (beta = 1.02 per G versus C allele; SE = 0.33; P = 0.0023) or KIS3 (beta = 1.47 per G versus C allele; SE = 0.34; P = 2.39e-5).
Genetic variants associated with the NMR in African American smokers (PNAT2 and KIS3 analysed separately)
In PNAT2, 56 chromosome 19 variants associated significantly (P < 5e-8) with the NMR were identified after adjusting for population substructure; 53 remained significant after controlling additionally for NMR covariates (Supporting information, Table S3 ). Controlling for clinical site did not alter the findings substantially (53 hits were still observed; rs12459249 remained the top hit with a beta (SE) per C versus T allele of 0.61 (0.066); P = 1.39e-18). A variant within chromosome 2 was also associated significantly with the NMR (rs16984355; P = 2.1e-9). The top overall variant identified in PNAT2 was rs12459249 (Figs 1a, 2a) , explaining 17.1% of NMR variation. Thirty-five of the 56 significant hits were not genome-wide significant in the~1500 Finnish Europeans [16] ; the most significant of these hits was rs2644890 (Table 2 and Figs 3a, 4a), explaining 2.3% of NMR variation after controlling for rs12459249. Per 1000 genomes, rs12459249 and rs2644890 are not in appreciable linkage disequilibrium (LD) in individuals of African descent (r 2 < 0.20). The rs2644890 variant was also associated significantly with the NMR in KIS3 (P = 1.24e-7; Figs 3b, 4b) and KIS2 (P = 5.60e-5; Fig. 4c ). In KIS3, 46 chromosome 19 variants associated significantly (P < 5e-8) with the NMR were identified after adjusting for population substructure; 38 (> 80%) of these variants were also genome-wide significant in PNAT2. After additionally controlling for NMR covariates, 44 chromosome 19 variants remained significant (Supporting information, Table S4 ). A variant within chromosome 2 was also associated significantly with the NMR (rs139278877; P = 5.2e-9). The top overall variant in KIS3 was rs11878604 (Table 2) , accounting for 17.1% of NMR variation; rs11878604 was also significant in PNAT2 (P = 9.60e-17; Table 2 ). Twenty-eight of the 46 significant hits in KIS3 were not genome-wide significant in the~1500 Finnish Europeans [16] ; the most significant of these hits was rs111825958 (Table 2 and Figs 3d, 4e), which explained 0.8% of NMR variation after controlling for rs11878604. Per 1000 genomes, rs11878604 and rs111825958 are in moderate LD in individuals of African descent (r 2 = 0.39). The rs111825958 variant was also associated significantly with the NMR in PNAT2 (P = 4.11e-10; Figs 3c, 4d) and KIS2 (P = 4.25e-11; Fig. 4f ). Of note, the previously characterized non-synonymous rs28399454 (C > T) variant in exon 7 of CYP2A6, which defines the non-functional CYP2A6*17 allele In PNAT2, genome-wide association study (GWAS) results were adjusted for principal components 1 and 2, sex, age, body mass index (BMI) and the use of mentholated cigarettes. In KIS3, GWAS results were adjusted for principal components 1 and 2, sex, age and BMI. The genomic inflation factor score (λ) in each population was 1 and therefore not adjusted for in the meta-analysis. PNAT = Pharmacogenetics of Nicotine Addiction Treatment; KIS = Kick-it-at-Swope; SE = standard error.
present at high frequency in AAs [33] , was associated significantly with the NMR in both PNAT2 (P = 4.56e-11; beta = À0.68 per T versus C allele; SE = 0.10, allele frequency = 10.5%) and KIS3 (P = 5.90e-11; beta = À0.68 per T versus C allele; SE = 0.10 allele frequency = 11.0%). In a model that controlled for population substructure, cohort-specific NMR covariates and additionally for rs28399454, the P-values for rs12459249 in PNAT2 and KIS3 increased somewhat (from 1.59e-18 to 1.03e-11, and from 3.41e-19 to 1.13e-11, respectively). However, the P-value for rs111645190 was not genome-wide significant in each of PNAT2 and KIS3 after controlling for rs28399454: P-values increased from 4.10e-10 to 0.023 in PNAT2 and from 6.88e-14 to 0.011 in KIS3.
DISCUSSION
This is the first NMR GWAS conducted exclusively in African Americans. We identified three independent signals tagged by rs12459249, rs111645190 and rs185430475. These three signals were not in LD (r 2 < 0.20) with (in the 1000 Genomes Project AFR population) the four independent signals (rs56113850, rs113288603, esv2663194 and rs12461964) identified in the first NMR GWAS, which we conducted in~1500 Finnish European smokers [16] . Taken together, these findings extend our prior work (e.g. for *23, *24, *25, *28, *35 and *39-*45 [29] [30] [31] [32] ) showing the existence of unique genetic influences on CYP2A6 function and the NMR in AA.
The top independent signal, rs12459249, located~9.5 kb 3 0 of CYP2A6, was also genome-wide significant in the Finnish sample [16] , suggesting a common ancestral origin; however, it is possible that rs12459249 tags different functional variants in different populations. After controlling for rs28399454, the defining variant in the CYP2A6*17 allele present at high frequencies in AA [33] , the P-values for rs12459249 in PNAT2 and KIS3 increased only somewhat (from~10 À18 to 10
À11
), suggesting that at least a portion of the influence of rs12459249 on the NMR is independent of CYP2A6*17. A recent study examined the NMR following oral or intravenous (i.v.) administration of labelled nicotine and cotinine in n = 212, n = 51 and n = 49 individuals of EA, Asian American and AA ancestry, respectively, and identified rs12459249 as the top-ranked SNP overall; rs12459249 was also associated non-significantly with the NMR (P = 5.76e-6) in the small sample of AA [35] .
The second independent signal was tagged by rs111645190, located~5.5 kb 5 0 of CYP2A6. The top two independent variants (rs12459249 and rs111645190) explained~20% of NMR variation, comparable to the amount of variability captured in the~1500 Finnish European smokers [16] , where the independent signals explained~18-31% of NMR variation. However, the influence of rs111645190 on the NMRwas no longer significant in either PNAT2 or KIS3 after controlling for rs28399454 (CYP2A6*17 allele), suggesting that this second independent signal is driven largely by rs28399454 [33] . Of note, more than half (~60%) of the 96 hits found in the meta-analysis were not genome-wide significant in thẽ 1500 Finnish Europeans [16] , reflecting in part a unique population LD structure. The top unique variant in the meta-analysis, rs111825958, was also associated with the NMR in KIS2 [38] . After controlling for rs28399454 Figure 3 rs2644890 and rs111825958 were the top unique variants associated significantly with the nicotine metabolite ratio (NMR) in Pharmacogenetics of Nicotine Addiction Treatment (PNAT)2 and Kick-it-at-Swope (KIS)3 African American smokers, respectively. The top (i.e. smallest P-value) unique variant associated with the NMR in PNAT2 was rs2644890. LocusZoom plots depicting rs2644890 (indicated with a diamond) in PNAT2 and KIS3 are shown in (a) and (b), respectively. P-values are adjusted for principal components 1 and 2. The top (i.e. smallest P-value) unique variant associated with the NMR in KIS3 was rs111825958. LocusZoom plots depicting rs111825958 (indicated with a diamond) in PNAT2 and KIS3 are shown in (c) and (d), respectively. P-values are adjusted for principal components 1 and 2. Linkage disequilibrium (LD) patterns are based upon the hg19/1000 Genomes November 2014 release AFR reference population. [Colour figure can be viewed at wileyonlinelibrary.com] (CYP2A6*17), the P-values in PNAT2 and KIS3 increased from 4.11e-10 to 0.018 and from 5.28e-16 to 1.18e-5, respectively, suggesting, as for rs111645190, that rs28399454 explains a large portion of the influence of rs111825958 on the NMR.
Our previous NMR GWAS in~1500 Finnish European smokers [16] identified > 700 hits, all found on chromosome 19q13 in or near to the CYP2A6 locus. The top hit, rs56113850, located in intron 4 of CYP2A6, also replicated in the EA participants from the smaller GWAS of laboratory-based NMR [35] . A subsequent GWAS of urinary NMR, conducted in~2200 smokers (including n = 364 AA) from a prospective multi-ethnic cohort study, identified 248 variants (~99% of which were within or near CYP2A6) associated significantly with the NMR, and replicated this top hit (rs56113850) [36] . The and African descent individuals, respectively; 1000 genomes data), suggest that these SNPs should be included routinely in genotyping platforms for genomic investigations of nicotine metabolism and smoking cessation. GTEx expression quantitative trait loci analyses suggest that rs12459249 is associated with CYP2A6 protein expression in the lung, and possibly liver (effect size = 0.12 for C versus T), while rs56113850 has a greater relative (versus rs12459249) influence on liver CYP2A6 mRNA expression (effect size = 0.26 for C versus T). Because the NMR is 80% heritable (estimated in Finnish twins) [16] , mediated largely by a single enzyme (i.e. CYP2A6), and not altered appreciably by environmental factors [17] , the usefulness of CYP2A6 genetics for personalizing therapy and understanding tobacco-related disease risk shows great promise. However, the NMR can only be used reliably to assess CYP2A6 activity in current, regular (i.e. daily) smokers [12] [13] [14] , while CYP2A6 genetics could be used to predict activity phenotype in current, former and non-smokers in epidemiological investigations of cancer risk, for example. Thus, it is likely that a CYP2A6 genetics-based approach could have greater utility and wider applicability compared to the NMR. In addition, because CYP2A6 also metabolizes therapeutic drugs including letrozole [53] and tegafur [54] , two chemotherapeutics, as well as other drugs (e.g. efavirenz, metronidazole, artemisinin, valproic acid) [55] , the usefulness of CYP2A6 genetics in personalized medicine approaches extends beyond tobacco dependence.
Several limitations of our work warrant mention. By virtue of the genome-wide genotyping chip, we were unable to examine structural variation adequately in CYP2A6. Copy number variation, such as the CYP2A6*1XA duplication and CYP2A6*4 deletion variants [46] , is known to alter CYP2A6 activity; it is possible that known and/or novel copy number variants in CYP2A6 are in LD with the variants identified in our study. In addition, the lack of overlap in signals observed between AA and European descent smokers may be due, in part, to differences in the genotyping platforms used, reference panels for imputation, quality control/imputation/MAF filtering pipelines, as well as potential inter-ethnic variation in environmental confounding factors and/or additional potential differences between smokers seeking treatment versus those who are not. However, head-to-head comparisons of NMR GWAS signals in PNAT2 AA and PNAT2 European-descent smokers, analysed using an identical genotyping platform and phase I release of 1000 genomes, also indicate a substantial lack of overlap (unpublished observations). Finally, analysing treatment-seeking smokers may limit generalizability to general smoking populations; however, personalized medicine approaches based on CYP2A6 or the NMR would be targeted to treatmentseeking smokers, and future GWAS in treatment-seeking smokers from other ethnic backgrounds should be considered. Future larger studies may identify important signals outside CYP2A6 that influence the NMR.
In summary, we identified three independent signals in the largest NMR GWAS of AA smokers performed to date, accounting for~20% of the total variability in the NMR.
More than half (~60%) of the 96 total hits were not found in the largest NMR GWAS of European descent smokers [16] , and might contribute to unique regulation of CYP2A6 in AA. Further investigation of these hits, including haplotype characterization and functional assessments, will help to identify which variants are causally influencing the NMR beyond known functional variants (e.g. CYP2A6*17 [33] ). There may also be rare CYP2A6 variants [56, 57] with substantial impacts on the NMR; future sequencing-based studies will complement GWAS approaches and may improve further our understanding of the genetic influences on the NMR. Determining whether these genetic variants influence other phenotypes, including smoking cessation, will set the stage for genomicsbased personalization of tobacco dependence treatment. Functional characterization studies may also provide insight into inter-ethnic variability in nicotine metabolism/CYP2A6 activity and resulting smoking behaviours and tobacco-related disease risk.
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R.F.T. has consulted in the past for Apotex on unrelated topics. N.L.B. has consulted with pharmaceutical companies that market smoking cessation medications and has been a paid expert witness in litigation against tobacco companies. P.M.C. served on the scientific advisory board of Pfizer, conducted educational talks sponsored by Pfizer on smoking cessation (2006) (2007) (2008) , and has received grant support from Pfizer. R.A.S. has provided consultation to Pfizer and GlaxoSmithKline. Pfizer Inc. provided varenicline and placebo pills at no cost for the PNAT2 clinical trial. The funders had no role in study design, data collection and analysis, decision to publish or preparation of the manuscript. Figure S1 Quality control pipeline utilized in Pharmacogenetics of Nicotine Addiction Treatment (PNAT2) and Kickit-at-Swope (KIS3) smokers prior to genome-wide association study (GWAS) analysis. The quality control (QC) steps for both samples and markers (i.e. variants) carried out prior to analysis are depicted in chronological order. The original sample sizes were: n = 1687 PNAT2 smokers (self-reported Caucasian, African or African American, Asian, Native American, Hawaiian/Polynesian, multiracial, or other) and n = 502 KIS3 smokers (self-reported African American). Sample QC on PNAT2 and KIS3 was performed separately for steps 1 and 2. The PNAT2 and KIS3 samples remaining following sample QC step 2 were analysed together for relatedness (step 3) and ancestry determination (step 4). Remaining sample QC (step 5; heterozygosity determination) and all marker QC (steps 6-8) were performed separately for PNAT2 AA and KIS3 AA. The final numbers of samples and markers remaining after sample and marker QC are indicated in the grey boxes. The final number of PNAT2 AA and KIS3 AA samples remaining after sample, marker and biomarker QC (step 9) are indicated in the black boxes. There were n = 406 PNAT2 AA individuals available for final analyses after excluding those with missing menthol data (n = 98) and n = 449 KIS3 AA individuals were available for final analyses after excluding one participant with missing BMI data. IBS = identity by state; PCA = principal components analysis; PC = principal component; SD = standard deviation; AA = African American. Figure S2 Ancestry clustering in Pharmacogenetics of Nicotine Addiction Treatment (PNAT2) and Kick-it-at-Swope (KIS3) smokers using HapMap 3 as a reference population. Principal components 1 and 2, generated from sample quality control (QC) step 4 (see Fig. S1 cestry for PNAT2 and KIS3 was determined using the following cut-points: principal component 1 ≤ À0.025, and principal component 2 ≤ 0.01, indicated with black dotted lines. These conservative thresholds were selected to ensure homogeneity of the population and were chosen based on visual inspection of the plot. Figure S3 Histograms depicting the distribution of the nicotine metabolite ratio (NMR) and square-root NMR in Pharmacogenetics of Nicotine Addiction Treatment (PNAT2) and Kick-it-at-Swope (KIS3) and KIS2 African American smokers. The NMR distribution is shown in PNAT2 (a), KIS3 (b) and KIS2 (c) African American smokers. The square-root NMR distribution is shown in PNAT2 (d), KIS3 (e) and KIS2 (f) African American smokers. NMR was square-root-transformed to help correct for positive skew. SD = standard deviation. Figure S4 Quantile-quantile (QQ) plots of the square-root nicotine metabolite ratio (NMR) GWAS results in Pharmacogenetics of Nicotine Addiction Treatment (PNAT2) and Kick-it-at-Swope (KIS3) African American smokers. QQ plots of the full results of the square-root NMR GWAS are shown in PNAT2 (a) and KIS3 (b), and after excluding genome-wide significant hits in PNAT2 (c) and KIS3 (d). Expected P-values are those expected under the null hypothesis. The shaded area around the red line indicates the 95% confidence interval under the null. 
